報價延遲最少15分鐘:2025/01/12 03:36 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
696.88 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
40.43/51.71
|
|
企業價值
83.32B
|
| 資產負債 |
|
每股賬面淨值
266.87
|
| 現金流量 |
|
現金流量率
0.05
|
| 損益表 |
|
收益
13.12B
|
|
每股收益
119.19
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/01/12 03:36 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |